Cargando…

The Proper Administration Sequence of Radiotherapy and Anti-Vascular Agent—DMXAA Is Essential to Inhibit the Growth of Melanoma Tumors

SIMPLE SUMMARY: The growth of tumors depends on the development of their abnormal vasculature. Targeting tumor blood vessels could be an effective approach to anti-cancer therapy. One of the strategies is targeting existing tumor blood vessels—anti-vascular therapy. Anti-vascular drugs destroy the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drzyzga, Alina, Cichoń, Tomasz, Czapla, Justyna, Jarosz-Biej, Magdalena, Pilny, Ewelina, Matuszczak, Sybilla, Wojcieszek, Piotr, Urbaś, Zbigniew, Smolarczyk, Ryszard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394873/ https://www.ncbi.nlm.nih.gov/pubmed/34439079 http://dx.doi.org/10.3390/cancers13163924

Ejemplares similares

Brachytherapy in a Single Dose of 10Gy as an “in situ” Vaccination
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2020)

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context
por: Czapla, Justyna, et al.
Publicado: (2023)

Mesenchymal stromal cells as carriers of IL-12 reduce primary and metastatic tumors of murine melanoma
por: Kułach, Natalia, et al.
Publicado: (2021)

The Effect of Radiotherapy on Cell Survival and Inflammatory Cytokine and Chemokine Secretion in a Co-Culture Model of Head and Neck Squamous Cell Carcinoma and Normal Cells
por: Matuszczak, Sybilla, et al.
Publicado: (2023)

Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2018)

Author Correction: Combination of anti-vascular agent - DMXAA and HIF-1α inhibitor - digoxin inhibits the growth of melanoma tumors
por: Smolarczyk, Ryszard, et al.
Publicado: (2020)

Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2015)

The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells
por: Czapla, Justyna, et al.
Publicado: (2019)

M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2018)

Characteristic of c-Kit(+) progenitor cells in explanted human hearts
por: Matuszczak, Sybilla, et al.
Publicado: (2014)

Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2019)

Human Cardiac Mesenchymal Stromal Cells with CD105(+)CD34(-) Phenotype Enhance the Function of Post-Infarction Heart in Mice
por: Czapla, Justyna, et al.
Publicado: (2016)

D-K(6)L(9) Peptide Combination with IL-12 Inhibits the Recurrence of Tumors in Mice
por: Cichoń, Tomasz, et al.
Publicado: (2014)

Monitoring of diffusion properties and transverse relaxation time of mouse ischaemic muscle after administration of human mesenchymal stromal cells derived from adipose tissue
por: Skorupa, Agnieszka, et al.
Publicado: (2019)

Human ADSC xenograft through IL-6 secretion activates M2 macrophages responsible for the repair of damaged muscle tissue
por: Pilny, Ewelina, et al.
Publicado: (2019)

Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression
por: Rauca, Valentin-Florian, et al.
Publicado: (2021)

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease
por: Charvátová, Sandra, et al.
Publicado: (2023)

Transcriptomes of human mesenchymal cells isolated from the right ventricle and epicardial fat differ strikingly both directly after isolation and long‐term culture
por: Stępniewski, Jacek, et al.
Publicado: (2019)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Antitumor Effects of Recombinant Antivascular Protein ABRaA-VEGF(121) Combined with IL-12 Gene Therapy
por: Ciomber, Agnieszka, et al.
Publicado: (2013)

Prognostic Significance of STING Immunoexpression in Relation to HPV16 Infection in Patients with Squamous Cell Carcinomas of Oral Cavity and Oropharynx
por: Biesaga, Beata, et al.
Publicado: (2022)

Discovery of Novel STING Inhibitors Based on the Structure of the Mouse STING Agonist DMXAA
por: Chang, Jiajia, et al.
Publicado: (2023)

Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
por: Motais, Benjamin, et al.
Publicado: (2021)

Lightweight ProteinUnet2 network for protein secondary structure prediction: a step towards proper evaluation
por: Stapor, Katarzyna, et al.
Publicado: (2022)

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis
por: Roberts, Zachary J., et al.
Publicado: (2007)

Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines
por: Peng, Shiwen, et al.
Publicado: (2011)

The Chemotherapeutic Agent DMXAA as a Unique IRF3-Dependent Type-2 Vaccine Adjuvant
por: Tang, Choon Kit, et al.
Publicado: (2013)

Binding-Pocket and Lid-Region Substitutions Render Human STING Sensitive to the Species-Specific Drug DMXAA
por: Gao, Pu, et al.
Publicado: (2014)

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
por: Weiss, Julia M., et al.
Publicado: (2017)

The Proper Diet and Regular Physical Activity Slow Down the Development of Parkinson Disease
por: Chromiec, Patryk Andrzej, et al.
Publicado: (2021)

To-Do and Not-To-Do in Model Studies of the Uptake, Fate and Metabolism of Metal-Containing Nanoparticles in Plants
por: Wojcieszek, Justyna, et al.
Publicado: (2020)

Effect of Heme Oxygenase-1 on Melanoma Development in Mice—Role of Tumor-Infiltrating Immune Cells
por: Was, Halina, et al.
Publicado: (2020)

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
por: Zhao, L, et al.
Publicado: (2002)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent
por: Jameson, M B, et al.
Publicado: (2003)

Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
por: Lash, C. J., et al.
Publicado: (1998)

The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model
por: Graham, Peter T., et al.
Publicado: (2022)

Ocular Complications of Radiotherapy in Uveal Melanoma
por: Zemba, Mihail, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h4jjs090b6c091iogd8s25jjk4